Effectiveness of Endocrine Therapy in Luminal-A Breast Cancer Patients: A Literature Review

Jeremiah Nugraha Mai; M. Rizky Ferdiaananda; Muhammad Nur Hidayah Rayhan Wiradiharja; Shabrina Nur Afiati; Muhammad Alif Fahren Subangkit

doi:10.37287/ijghr.v6i4.3083

Jeremiah Nugraha Mai School of Medicine and Health Sciences, Universitas Katolik Indonesia Atma Jaya
M. Rizky Ferdiaananda Faculty of Medicine, Universitas HKBP Nommensen
Muhammad Nur Hidayah Rayhan Wiradiharja Faculty of Medicine, Universitas Padjadjaran
Shabrina Nur Afiati Faculty of Medicine, Universitas Trisakti
Muhammad Alif Fahren Subangkit Faculty of Medicine, Universitas Jambi

DOI: https://doi.org/10.37287/ijghr.v6i4.3083

Keywords: breast cancer, endocrine, luminal A, therapy

Abstract

Breast cancer ranks as one of the primary causes of mortality in women worldwide, with Southeast Asia, particularly Indonesia, witnessing a notable prevalence. Objective: To elaborate the endocrine therapy in breast cancer patients. Method: A comprehensive literature search was done across PubMed, Medline, ProQuest, Sage, and Google Scholar. Breast cancer, carcinoma mammae, luminal A, endocrine therapy, and recurrence rate, were used as the keywords. Inclusion criteria were studies on endocrine therapy in breast cancer. Initial search using title and abstract was conducted, then followed by full-text screening. Results: From 415 studies, 11 articles published between 2003 and 2022 were retrieved [RCT (n=8), clinical trial (n=1), cohort (n=1), cross-sectional (n=1)]. Endocrine therapy, also known as hormone therapy, could inhibit the growth of tumor cells by slowing down the ability of those cells to replicate. Fulvestrant and aromatase inhibitors (AI) such as anastrozole and letrozole have shown high survival and low recurrence rates. Conclusions: Adjuvant endocrine or hormonal therapy had shown remarkable outcomes for luminal A breast cancer patients, with high survival rates and very low recurrence rates. Further research was still needed to further understand the development of future treatments and to extend the research on long-term survival rates.

References

Acheampong, T., Kehm, R. D., Terry, M. B., Argov, E. L., & Tehranifar, P. (2020). Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016. JAMA Network Open, 3(8), e2013226. https://doi.org/10.1001/jamanetworkopen.2020.13226

Drăgănescu, M., & Carmocan, C. (2017). Hormone Therapy in Breast Cancer. Chirurgia, 112(4), 413. https://doi.org/10.21614/chirurgia.112.4.413

Eliyatkin, N., Yalcin, E., Zengel, B., Aktaş, S., & Vardar, E. (2015). Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. Journal of Breast Health, 11(2), 59–66. https://doi.org/10.5152/tjbh.2015.1669

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., Bonnefoi, H. R., Bellet, M., Martino, S., Geyer, C. E., Goetz, M. P., Stearns, V., Pinotti, G., Puglisi, F., Spazzapan, S., … Regan, M. M. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 379(2), 122–137. https://doi.org/10.1056/NEJMoa1803164

Gao, J. J., & Swain, S. M. (2018). Luminal A Breast Cancer and Molecular Assays: A Review. The Oncologist, 23(5), 556–565. https://doi.org/10.1634/theoncologist.2017-0535

Harbeck, N., & Gnant, M. (2017). Breast cancer. Lancet (London, England), 389(10074), 1134–1150. https://doi.org/10.1016/S0140-6736(16)31891-8

Howell, A., Pippen, J., Elledge, R. M., Mauriac, L., Vergote, I., Jones, S. E., Come, S. E., Osborne, C. K., & Robertson, J. F. R. (2005). Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer, 104(2), 236–239. https://doi.org/10.1002/cncr.21163

Huang, G., Lu, H., Chen, Q., & Huang, X. (2022). Prevalence and Factors Associated with BRCA1/2 Gene Mutation in Chinese Populations with Breast Cancer. International Journal of General Medicine, Volume 15, 6783–6789. https://doi.org/10.2147/IJGM.S378706

Huang, H., Zhou, J., Chen, H., Li, J., Zhang, C., Jiang, X., & Ni, C. (2021). The immunomodulatory effects of endocrine therapy in breast cancer. Journal of Experimental & Clinical Cancer Research, 40(1), 19. https://doi.org/10.1186/s13046-020-01788-4

International Breast Cancer Study Group (IBCSG). (2003). Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. JNCI Journal of the National Cancer Institute, 95(24), 1833–1846. https://doi.org/10.1093/jnci/djg119

Jung, S. U., Sohn, G., Kim, J., Chung, I. Y., Lee, J. W., Kim, H. J., Ko, B. S., Son, B. H., Ahn, S.-H., Yang, S. W., & Lee, S. B. (2019). Survival outcome of adjuvant endocrine therapy alone for patients with lymph node-positive, hormone-responsive, HER2-negative breast cancer. Asian Journal of Surgery, 42(10), 914–921. https://doi.org/10.1016/j.asjsur.2019.01.003

Li, Z., Wei, H., Li, S., Wu, P., & Mao, X. (2022). The Role of Progesterone Receptors in Breast Cancer. Drug Design, Development and Therapy, Volume 16, 305–314. https://doi.org/10.2147/DDDT.S336643

Machackova, E., Claes, K., Mikova, M., Hazova, J., Stahlova Hrabincova, E., Vasickova, P., Trbusek, M., Navratilova, M., Svoboda, M., & Foretova, L. (2019). Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI – Current Developments for the Classifi cation of Variants. Klinicka Onkologie, 32(Suppl 2). https://doi.org/10.14735/amko2019S51

Mauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. A. (2006). Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. JNCI: Journal of the National Cancer Institute, 98(18), 1285–1291. https://doi.org/10.1093/jnci/djj357

Nielsen, T. O., Jensen, M.-B., Burugu, S., Gao, D., Jørgensen, C. L. T., Balslev, E., & Ejlertsen, B. (2017). High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clinical Cancer Research, 23(4), 946–953. https://doi.org/10.1158/1078-0432.CCR-16-1278

Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H. (2015). Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer: Basic and Clinical Research, 9s2, BCBCR.S29420. https://doi.org/10.4137/BCBCR.S29420

Pan, H., Gray, R. G., Davies, C., Peto, R., Bergh, J. C. S., Pritchard, K. I., Dowsett, M., & Hayes, D. F. (2016). Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). Journal of Clinical Oncology, 34(15_suppl), 505–505. https://doi.org/10.1200/JCO.2016.34.15_suppl.505

Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014). Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential. Steroids, 90, 13–29. https://doi.org/10.1016/j.steroids.2014.06.012

Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Price, K. N., Coates, A. S., Goldhirsch, A., & Gelber, R. D. (2016). Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology, 34(19), 2221–2231. https://doi.org/10.1200/JCO.2015.64.3171

Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., Láng, I., Wardley, A., Rabaglio, M., Price, K. N., Gelber, R. D., Coates, A. S., & Thürlimann, B. (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. The Lancet Oncology, 12(12), 1101–1108. https://doi.org/10.1016/S1470-2045(11)70270-4

Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., Ruiz-Borrego, M., Shao, Z., Noguchi, S., Rowbottom, J., Stuart, M., Grinsted, L. M., Fazal, M., & Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet, 388(10063), 2997–3005. https://doi.org/10.1016/S0140-6736(16)32389-3

Shien, T., & Iwata, H. (2020). Adjuvant and neoadjuvant therapy for breast cancer. Japanese Journal of Clinical Oncology, 50(3), 225–229. https://doi.org/10.1093/jjco/hyz213

Trayes, K. P., & Cokenakes, S. E. H. (2021). Breast Cancer Treatment. American Family Physician, 104(2), 171–178.

Tremont, A., Lu, J., & Cole, J. T. (2017). Endocrine Therapy for Early Breast Cancer: Updated Review. Ochsner Journal, 17(4), 405–411.

Water, W., Bastiaannet, E., Hille, E. T. M., Meershoek-Klein Kranenbarg, E. M., Putter, H., Seynaeve, C. M., Paridaens, R., Craen, A. J. M., Westendorp, R. G. J., Liefers, G.-J., & Velde, C. J. H. (2012). Age-Specific Nonpersistence of Endocrine Therapy in Postmenopausal Patients Diagnosed with Hormone Receptor–Positive Breast Cancer: A TEAM Study Analysis. The Oncologist, 17(1), 55–63. https://doi.org/10.1634/theoncologist.2011-0037

Widiana, I. K., & Irawan, H. (2020). Clinical and Subtypes of Breast Cancer in Indonesia. Asian Pacific Journal of Cancer Care, 5(4), 281–285. https://doi.org/10.31557/apjcc.2020.5.4.281-285.